Drug Trial Radar · NCT07796646
Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
81
Planned (sponsor's estimate)
Start
Oct 5, 2026
Primary completion
Feb 28, 2030
Study completion Mar 2030
Sponsor
- Lead sponsor
- Laboratoires TheaIndustry
- Sponsor type
- Industry
- Collaborators
- Sepul Bio
- First posted
- Sep 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 2 Open-label study is to evaluate the long-term safety and tolerability of Ultevursen administered via intravitreal injection (IVT) in participants with Retinitis Pigmentosa due to mutations in exon 13 of the USH2A gene. This is a multicenter study which will enroll approximately 81 participants, however, the exact number enrolled will depend on the final number completing the 24-month LUNA trial and are eligible and willing to enroll in CAPELLA.
Conditions
- Retinitis Pigmentosa (RP)
- Usher Syndrome Type 2
- Deaf Blind
- Retinal Disease
- Eye Diseases, Hereditary
- Eye Disorders Congenital
- Vision Disorders
Interventions
No intervention, will not receive any active study interventionOther
Observation only (no experimental drug administered)
Intravitreal Injection of UltevursenDrug
Participants will receive up to 4 doses over a 24-month period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of ocular adverse events (AEs), including serious AEs (SAEs) and adverse events of special interest (AESI)Time frame: 24 Months
- Incidence and severity of non-ocular AEs, including SAEs.Time frame: 24 Months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.